New combo before surgery aims to boost stomach cancer outcomes

NCT ID NCT07059299

First seen Jan 11, 2026 · Last updated May 09, 2026 · Updated 16 times

Summary

This early-phase trial tests a new combination of the immunotherapy drug tislelizumab plus chemotherapy (FLOT) given before surgery for people with stomach, esophageal, or junction cancer that can be removed. The goal is to see if the combination is safe and works well enough to study further. About 18 adults with locally advanced but resectable cancer will receive up to 8 cycles of the combo before surgery, instead of the standard 4 before and 4 after.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hämatologisch-Onkologische Praxis Eppendorf (hope)

    NOT_YET_RECRUITING

    Hamburg, 20249, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Klinikum rechts der Isar München der TU München

    RECRUITING

    München, 81675, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Krankenhaus Nordwest GmbH Institut für Klinisch-Onkologische Forschung (IKF)

    RECRUITING

    Frankfurt, 60488, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Universitätsklinikum Leipzig

    NOT_YET_RECRUITING

    Leipzig, 04103, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.